Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 2-Part, Phase 2, Open-Label Study of the Safety, Tolerability, and Efficacy of Itacitinib Immediate Release in Participants With Primary Myelofibrosis or Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis) Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy

NCT04629508 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT04629508
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04629508 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 2-Part, Phase 2, Open-Label Study of the Safety, Tolerability, and Efficacy of Itacitinib Immediate Release in Participants With Primary Myelofibrosis or Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis) Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy
Lead sponsor
Incyte Corporation
Phase
Phase 2
Overall status
Completed
Start date
July 12, 2021
Completion date
August 24, 2023
Enrollment
4 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

myelofibrosis, polycythemia vera, thrombocythemia